JPMorgan Chase & Co. Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target cut by research analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an "overweight" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s price objective would suggest a potential upside of 70.27% from the company's current price.

A number of other research analysts also recently weighed in on REGN. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Robert W. Baird lowered their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research report on Tuesday, February 4th. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. Finally, Wells Fargo & Company cut their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $966.88.

Remove Ads

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded down $23.35 during mid-day trading on Monday, reaching $587.29. The company's stock had a trading volume of 613,585 shares, compared to its average volume of 681,989. The firm's fifty day moving average price is $678.75 and its two-hundred day moving average price is $785.70. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market cap of $64.21 billion, a P/E ratio of 15.35, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals has a 12-month low of $585.66 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $11.86 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of REGN. Moody National Bank Trust Division boosted its stake in shares of Regeneron Pharmaceuticals by 3.5% during the 1st quarter. Moody National Bank Trust Division now owns 1,551 shares of the biopharmaceutical company's stock worth $984,000 after purchasing an additional 53 shares during the period. Versant Capital Management Inc boosted its position in shares of Regeneron Pharmaceuticals by 334.6% during the first quarter. Versant Capital Management Inc now owns 226 shares of the biopharmaceutical company's stock valued at $143,000 after buying an additional 174 shares during the period. First Hawaiian Bank boosted its position in shares of Regeneron Pharmaceuticals by 21.5% during the first quarter. First Hawaiian Bank now owns 3,639 shares of the biopharmaceutical company's stock valued at $2,308,000 after buying an additional 644 shares during the period. Boston Common Asset Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 25.3% during the first quarter. Boston Common Asset Management LLC now owns 27,343 shares of the biopharmaceutical company's stock valued at $17,342,000 after buying an additional 5,525 shares during the last quarter. Finally, Adirondack Trust Co. raised its holdings in shares of Regeneron Pharmaceuticals by 4.2% in the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after buying an additional 18 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.